Cancer Cell International (Jul 2022)

A pan-cancer analysis of thioredoxin-interacting protein as an immunological and prognostic biomarker

  • Xuxue Guo,
  • Mei Huang,
  • Haonan Zhang,
  • Qianhui Chen,
  • Ying Hu,
  • Yan Meng,
  • Changjie Wu,
  • Chenge Tu,
  • Yongfeng Liu,
  • Aimin Li,
  • Qingyuan Li,
  • Peirong Zhou,
  • Side Liu

DOI
https://doi.org/10.1186/s12935-022-02639-2
Journal volume & issue
Vol. 22, no. 1
pp. 1 – 16

Abstract

Read online

Abstract Background The critical role of thioredoxin-interacting protein (TXNIP) in cellular sulfhydryl redox homeostasis and inflammasome activation is already widely known, however, no pan-cancer analysis is currently available. Methods We thus first explored the potential roles of TXNIP across thirty-three tumors mainly based on The Cancer Genome Atlas and Gene Expression Omnibus datasets. Results TXNIP is lowly expressed in most cancers, and distinct associations exist between TXNIP expression and the prognosis of tumor patients. TXNIP expression was associated with tumor mutational burden, microsatellite instability, mismatch repair genes, tumor infiltrating immune cell abundance as well as cancer-associated fibroblasts. Moreover, ubiquitin mediated proteolysis, protein post-translational modification and other related pathways were involved in the functional mechanisms of TXNIP. Conclusions Our first pan-cancer study comprehensively revealed the carcinostatic role of TXNIP across different tumors. And this molecule may be considered as a potential immunological and prognostic biomarker.

Keywords